Document
type: Class

Continuant
type: Class

Entity
type: Class

Generically Dependent Continuant
type: Class

individual
rights: termsOfUse
date: 2026-08-24T21:51:30
publisher: vivo
type: Document
label: RDF description of Adverse Effects Associated with the First Dose of the Pfizer–BioNTech COVID-19 Vaccine in Healthcare Workers from Mexico: A Case Serie from Passive Surveillance - http://orbis.uaslp.mx/vivo/individual/d11327

Article
type: Class

Adverse Effects Associated with the First Dose of the Pfizer–BioNTech COVID-19 Vaccine in Healthcare Workers from Mexico: A Case Serie from Passive Surveillance
type: Continuant
estado: published
volume: 3
type: Entity
issue: 8
page end: 1219
type: Document
most specific type: Document
doi: 10.3390/covid3080085
related by: authorship_72912
type: Thing
crisid: 11328
type: Generically Dependent Continuant
page start: 1209
related by: authorship_72911
accesstype: Open Access
type: Information Content Entity
most specific type: Article
freetext keyword: COVID-19, SARS-CoV-2, COVID-19 vaccines, Vaccines, Drug-related side effects and adverse reactions
type: Article
related by: authorship_72913
has publication venue: COVID
abstract: Almost a year after the declaration of the pandemic due to the SARS-CoV-2 virus which causes the COVID-19 disease and the need to contain the progression and treatment, the promising option was designing an effective and safe vaccine to reach a state of massive immunity. The first vaccine approved was the one produced by Pfizer–BioNTech, and its application started in December 2020. Within days of the first applications, 0.2%25 of adverse events were reported. Herein, a series of 26 cases with the manifestation of adverse events related to the application of the first dose of the BNT162b2 vaccine from Pfizer–BioNTech in healthcare workers from Mexico. Of these cases, only five patients were classified with a certainty of anaphylaxis; two of them presented seizures, and their management is described individually. After the examination of all the cases, the symptoms were resolved. In Mexico and around the globe, the vaccination process continues, and the report of possible AEFIs is still needed to contribute to the pharmacovigilance of this new vaccine and improve its safety profile.
date time value: article date 11328

COVID
type: Entity
publication venue for: Adverse Effects Associated with the First Dose of the Pfizer–BioNTech COVID-19 Vaccine in Healthcare Workers from Mexico: A Case Serie from Passive Surveillance
type: Periodical
type: Thing
type: Generically Dependent Continuant
type: Information Content Entity
type: Continuant
type: Document
type: Collection
type: Journal

Information Content Entity
type: Class